DBV TECHNOLOGIES SA-SPON ADR (DBVT)
US23306J2006 - ADR
DBVT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. DBVT may be in some trouble as it scores bad on both profitability and health. DBVT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
DBVT had negative earnings in the past year.
In the past year DBVT has reported a negative cash flow from operations.
In the past 5 years DBVT always reported negative net income.
In the past 5 years DBVT always reported negative operating cash flow.
1.2 Ratios
DBVT has a Return On Assets of -63.70%. This is in the lower half of the industry: DBVT underperforms 61.14% of its industry peers.
DBVT has a Return On Equity of -91.83%. This is comparable to the rest of the industry: DBVT outperforms 47.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -63.7% | ||
| ROE | -91.83% | ||
| ROIC | N/A |
ROA(3y)-48.56%
ROA(5y)-53.59%
ROE(3y)-66.73%
ROE(5y)-73.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of DBVT (95.70%) is better than 95.90% of its industry peers.
In the last couple of years the Gross Margin of DBVT has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for DBVT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.7% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.65%
GM growth 5Y1.43%
2. Health
2.1 Basic Checks
DBVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DBVT has more shares outstanding
The number of shares outstanding for DBVT has been increased compared to 5 years ago.
The debt/assets ratio for DBVT is higher compared to a year ago.
2.2 Solvency
DBVT has an Altman-Z score of -1.35. This is a bad value and indicates that DBVT is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.35, DBVT perfoms like the industry average, outperforming 58.11% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that DBVT is not too dependend on debt financing.
DBVT has a Debt to Equity ratio of 0.09. This is in the lower half of the industry: DBVT underperforms 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.35 |
ROIC/WACCN/A
WACC7.15%
2.3 Liquidity
DBVT has a Current Ratio of 3.29. This indicates that DBVT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.29, DBVT is doing worse than 60.43% of the companies in the same industry.
DBVT has a Quick Ratio of 3.29. This indicates that DBVT is financially healthy and has no problem in meeting its short term obligations.
DBVT has a Quick ratio of 3.29. This is comparable to the rest of the industry: DBVT outperforms 41.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.29 |
3. Growth
3.1 Past
DBVT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.56%, which is quite good.
DBVT shows a strong growth in Revenue. In the last year, the Revenue has grown by 224.69%.
DBVT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.50% yearly.
EPS 1Y (TTM)19.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.69%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%-49.52%
3.2 Future
DBVT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.03% yearly.
The Revenue is expected to grow by 135.78% on average over the next years. This is a very strong growth
EPS Next Y-36.93%
EPS Next 2Y2.12%
EPS Next 3Y59.71%
EPS Next 5Y17.03%
Revenue Next Year13.08%
Revenue Next 2Y478.54%
Revenue Next 3Y481.18%
Revenue Next 5Y135.78%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for DBVT. In the last year negative earnings were reported.
Also next year DBVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
DBVT's earnings are expected to grow with 59.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.12%
EPS Next 3Y59.71%
5. Dividend
5.1 Amount
No dividends for DBVT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DBV TECHNOLOGIES SA-SPON ADR
NASDAQ:DBVT (11/22/2024, 8:00:00 PM)
After market: 0.46 -0.01 (-1.92%)0.469
-0.02 (-3.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap45.12M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -63.7% | ||
| ROE | -91.83% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.7% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.29 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)19.56%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-36.93%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y